Structured peptide processing
The invention relates to a method for modifying one or more peptide ligands, comprising polypeptides covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of providing one or more peptide ligands, wherein the polypeptide comprises two or more reactive groups which form a covalent linkage to the molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; exposing the peptide ligands to one or more proteases; and sorting the ligands according to the extent of proteolytic cleavage.
1. A method for preparing one or more peptide ligands, comprising polypeptides covalently linked to tris-(bromomethyl) benzene (TBMB) at two or more amino acid residues, comprising the steps of:
(a) displaying one or more peptide ligand in a phage display system, wherein the displayed polypeptide comprises two or more reactive groups, wherein the two or more reactive groups are conjugated to TBMB to form a covalent linkage to TBMB, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups;
wherein the TBMB is present at less than 100 μM during conjugating to the phage displayed polypeptide;
(b) exposing the phage displayed peptide ligands covalently linked to TBMB to one or more proteases; and
(c) screening the phage displayed peptide ligands covalently linked to TBMB for binding against a target, and selecting the phage displayed peptide ligands covalently linked to TBMB which bind to the target.
2. The method of claim 1 , wherein the phage displayed peptide ligands covalently linked to TBMB selected for binding to the target are resistant to protease cleavage.
3. The method of claim 1 , wherein exposure to the one or more proteases is carried out in the presence of a reducing agent.
4. The method of claim 1 , wherein the one or more peptide ligand is a repertoire of peptide ligands.
5. The method of claim 1 , wherein the phage displayed peptide ligands covalently linked to TBMB selected for binding to the target are susceptible to protease cleavage.
6. The method of claim 5 , wherein exposure to the one or more proteases is carried out in the presence of a reducing agent.
7. The method of claim 5 , wherein the one or more peptide ligands is a repertoire of peptide ligands.
8. The method of claim 1 , wherein the binding specificity of the phage displayed peptide ligands covalently linked to TBMB for the target is altered though protease cleavage of one or more peptide loops.
9. The method of claim 1 , wherein the phage displayed peptide ligands covalently linked to TBMB which bind to the target are further modified by (a) amino acid side chain modification or substitution; or (b) polypeptide backbone modification.
10. The method of claim 9 , wherein the backbone modification is selected from the group consisting of introducing, near the site of protease cleavage, a D-amino acid, a reduced peptide bond, and N-methylation.